Abstract
The following highlights key, current information for immunization providers on COVID-19 vaccines. The evidence on COVID-19 disease and vaccines is evolving. Evidence from clinical trial data is limited due to limitations in the size and duration of follow-up of trial populations; however, studies are ongoing. NACI will continue to monitor the data and update its recommendations as needed. Please refer to the remainder of the Statement for details.
- Recommendation
- Americas
- Canada
- Pfizer-BioNTech vaccine
- Moderna COVID-19 vaccine
- AstraZeneca COVID-19 vaccine
- COVID-19